FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W54188055> ?p ?o ?g. }

• W54188055 endingPage "5" @default.
• W54188055 startingPage "5" @default.
• W54188055 abstract "Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients Fabrizio Cantini1, Laura Niccoli1, Carlotta Nannini1, Olga Kaloudi1, Emanuele Cassarà1, Massimo Susini2, Ivo Lenzetti21Second Division of Internal Medicine, Rheumatology Unit, 2Division of Ophthalmology, Prato Hospital, Prato, ItalyPurpose: To evaluate the long-term efficacy of infliximab in patients with refractory Behçet’s disease (BD)-associated and idiopathic posterior uveitis (PU).Methods: Single center, prospective, 6-year duration, follow-up study on 50 consecutive patients (20 [40%] males and 30 [60%] females with a mean age of 37.5 ± 12.3 years) with refractory BD-associated PU (36 patients) and idiopathic PU (14 patients) who had failed at least one immunosuppressive drug. At baseline, patients received prednisone 1 mg/kg/day with rapid tapering and infliximab infusions (5 mg/kg) at weeks 0, 2, 6, and every 8 weeks thereafter. Nonresponders after the third infusion withdrew from the study. Primary outcome measures were visual acuity (VA) value improvement compared to baseline. Secondary outcome measures were proportion of patients with VA improvement from baseline; proportion of patients achieving disease remission; number of PU flare-ups; and incidence of adverse events.Results: At the final follow-up, mean right and left eye VA respectively increased from 0.57 ± 0.31 at baseline to 0.68 ± 0.33 (P = 0.048) and from 0.67 ± 0.28 to 0.76 ± 0.27 (P = 0.047). None of the patients had VA worsening and new onset ocular complications. A complete response of PU was recorded in 34/50 (68%) patients and partial response in 11/50 (22%). Five patients were nonresponders and withdrew from the study after the third infusion. A significant reduction of ocular attacks and of the proportion of patients with cystoid macular edema was observed. No differences in infliximab efficacy was recorded between patients with BD-associated and idiopathic PU. No serious adverse events occurred. The mean follow-up duration was 36.8 months.Conclusion: Long-term infliximab therapy was equally effective and safe with a significant VA gain in refractory BD-associated and idiopathic PU.Keywords: Behçet’s disease, idiopathic posterior uveitis, infliximab, posterior uveitis, visual acuity" @default.
• W54188055 created "2016-06-24" @default.
• W54188055 creator A5028253659 @default.
• W54188055 creator A5059722619 @default.
• W54188055 creator A5070823990 @default.
• W54188055 creator A5077870866 @default.
• W54188055 creator A5085880704 @default.
• W54188055 creator A5091280294 @default.
• W54188055 creator A5015030504 @default.
• W54188055 date "2011-12-01" @default.
• W54188055 modified "2023-10-17" @default.
• W54188055 title "Efficacy of infliximab in refractory Beh&ccedil;et&rsquo;s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients" @default.
• W54188055 cites W140822034 @default.
• W54188055 cites W1480728926 @default.
• W54188055 cites W1524996852 @default.
• W54188055 cites W1561580792 @default.
• W54188055 cites W1595194062 @default.
• W54188055 cites W1601972531 @default.
• W54188055 cites W164019415 @default.
• W54188055 cites W1682055284 @default.
• W54188055 cites W1914606342 @default.
• W54188055 cites W1979534828 @default.
• W54188055 cites W1980372288 @default.
• W54188055 cites W1981676742 @default.
• W54188055 cites W1981943982 @default.
• W54188055 cites W1987670655 @default.
• W54188055 cites W1989989349 @default.
• W54188055 cites W1991528145 @default.
• W54188055 cites W1994056390 @default.
• W54188055 cites W1994157670 @default.
• W54188055 cites W2002488023 @default.
• W54188055 cites W2002949291 @default.
• W54188055 cites W2010970060 @default.
• W54188055 cites W2011296007 @default.
• W54188055 cites W2011959542 @default.
• W54188055 cites W2013517074 @default.
• W54188055 cites W2014887512 @default.
• W54188055 cites W2030038299 @default.
• W54188055 cites W2030600946 @default.
• W54188055 cites W2031016978 @default.
• W54188055 cites W2036131677 @default.
• W54188055 cites W2049056531 @default.
• W54188055 cites W2059260177 @default.
• W54188055 cites W2060721487 @default.
• W54188055 cites W2061468832 @default.
• W54188055 cites W2064729318 @default.
• W54188055 cites W2071764271 @default.
• W54188055 cites W2072643599 @default.
• W54188055 cites W2072664035 @default.
• W54188055 cites W2076770794 @default.
• W54188055 cites W2079244819 @default.
• W54188055 cites W2087716361 @default.
• W54188055 cites W2108832576 @default.
• W54188055 cites W2111615368 @default.
• W54188055 cites W2111800737 @default.
• W54188055 cites W2112901522 @default.
• W54188055 cites W2114081005 @default.
• W54188055 cites W2120642391 @default.
• W54188055 cites W2121628076 @default.
• W54188055 cites W2122888527 @default.
• W54188055 cites W2139499737 @default.
• W54188055 cites W2147171610 @default.
• W54188055 cites W2149913504 @default.
• W54188055 cites W2155115933 @default.
• W54188055 cites W2155987419 @default.
• W54188055 cites W2157333305 @default.
• W54188055 cites W2157388487 @default.
• W54188055 cites W2157431984 @default.
• W54188055 cites W2158200396 @default.
• W54188055 cites W2158286914 @default.
• W54188055 cites W2170347817 @default.
• W54188055 cites W2461157698 @default.
• W54188055 cites W34961135 @default.
• W54188055 doi "https://doi.org/10.2147/btt.s27343" @default.
• W54188055 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3266861" @default.
• W54188055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22291462" @default.
• W54188055 hasPublicationYear "2011" @default.
• W54188055 type Work @default.
• W54188055 sameAs 54188055 @default.
• W54188055 citedByCount "16" @default.
• W54188055 countsByYear W541880552012 @default.
• W54188055 countsByYear W541880552013 @default.
• W54188055 countsByYear W541880552014 @default.
• W54188055 countsByYear W541880552016 @default.
• W54188055 countsByYear W541880552017 @default.
• W54188055 countsByYear W541880552018 @default.
• W54188055 countsByYear W541880552019 @default.
• W54188055 countsByYear W541880552020 @default.
• W54188055 countsByYear W541880552022 @default.
• W54188055 countsByYear W541880552023 @default.
• W54188055 crossrefType "journal-article" @default.
• W54188055 hasAuthorship W54188055A5015030504 @default.
• W54188055 hasAuthorship W54188055A5028253659 @default.
• W54188055 hasAuthorship W54188055A5059722619 @default.
• W54188055 hasAuthorship W54188055A5070823990 @default.
• W54188055 hasAuthorship W54188055A5077870866 @default.
• W54188055 hasAuthorship W54188055A5085880704 @default.
• W54188055 hasAuthorship W54188055A5091280294 @default.

• next